Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The nicotinic acetylcholine receptor (nAChR) α4α6β2 is a subtype of neuronal nAChRs, which are pentameric ligand-gated ion channels. These receptors respond to the neurotransmitter acetylcholine and the exogenous agonist nicotine. The nAChR α4α6β2 subtype is a heteromeric pentamer composed primarily of combinations of α4, α6, and β2 subunits, and is selectively expressed in dopaminergic and noradrenergic neurons. Activation induces prolonged depolarization that influences dopamine release, making it a key player in reward signaling and addiction. Its dysfunction has been implicated in addiction, Parkinson’s disease, neuropsychiatric disorders, and cognitive dysfunctions, making it a therapeutic target.
Agonist-induced cation channel opening leading to neuronal depolarization and downstream effects on neurotransmitter release. Antagonists block agonist binding and channel activation.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nicotinic Acetylcholine Receptor α4α6β2 (nAChR α4α6β2).